More importantly, these inhibitors demonstrated further effectiveness against glioma cells in combination with the first-line chemotherapeutic agent TMZ (Figure 6d), suggesting that the concurrent use of these inhibitors with each other or with other anticancer agents may become a novel therapeutic strategy against gliomas harboring KLC1-ROS1 fusion. This evidence concerns the gene KLC1 and glioma.